Nepafenac Once Daily for Macular Edema - Study 2

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
Epistemonikos ID: bf60700276243750dc1fb861760adbc1b08d312e
First added on: May 11, 2024